Appletree Medical Group

appletreemedicalgroup.com

For almost 30 years, Appletree Medical Group has focused on improving community healthcare. Thanks to years of continuous innovation, we have grown to become one of the largest multidisciplinary community health groups in Canada, preferred by both patients and health professionals alike. Whether by visiting one of our 75 medical centres or telemedicine sites, or connecting through our Virtual Care app, Appletree patients are given greater control over their healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

ACORDA THERAPEUTICS ANNOUNCES $16.5M AWARD AND ROYALTY/SUPPLY RELIEF IN AMPYRA® ARBITRATION CASE

Acorda Therapeutics, Inc. | October 17, 2022

news image

Acorda Therapeutics, Inc. announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC regarding licensing royalties relating to AMPYRA. Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel’s ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, ...

Read More

CELL AND GENE THERAPY

BIOTIMIZE ANNOUNCES THE OPENING OF A FUNDRAISING ROUND TO BUILD THE FIRST BIOLOGICAL CDMO IN BRAZIL

Biotimize | September 06, 2022

news image

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...

Read More

INDUSTRIAL IMPACT

CLOVER SELECTED FOR INCLUSION ON THE HANG SENG COMPOSITE INDEX

Clover Biopharmaceuticals | February 25, 2022

news image

Clover Biopharmaceuticals, Ltd. a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022. Hang Seng Composite Index Hang Seng Small Cap (Investable) Index Hang Seng Healthcare Index Hang Seng Hong Kong-Listed Biotech Index ...

Read More

INDUSTRIAL IMPACT

OMEGA THERAPEUTICS ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH STANFORD UNIVERSITY SCHOOL OF MEDICINE

Omega Therapeutics, Inc | October 14, 2021

news image

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

Read More
news image

MEDTECH

ACORDA THERAPEUTICS ANNOUNCES $16.5M AWARD AND ROYALTY/SUPPLY RELIEF IN AMPYRA® ARBITRATION CASE

Acorda Therapeutics, Inc. | October 17, 2022

Acorda Therapeutics, Inc. announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC regarding licensing royalties relating to AMPYRA. Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel’s ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, ...

Read More
news image

CELL AND GENE THERAPY

BIOTIMIZE ANNOUNCES THE OPENING OF A FUNDRAISING ROUND TO BUILD THE FIRST BIOLOGICAL CDMO IN BRAZIL

Biotimize | September 06, 2022

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...

Read More
news image

INDUSTRIAL IMPACT

CLOVER SELECTED FOR INCLUSION ON THE HANG SENG COMPOSITE INDEX

Clover Biopharmaceuticals | February 25, 2022

Clover Biopharmaceuticals, Ltd. a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022. Hang Seng Composite Index Hang Seng Small Cap (Investable) Index Hang Seng Healthcare Index Hang Seng Hong Kong-Listed Biotech Index ...

Read More
news image

INDUSTRIAL IMPACT

OMEGA THERAPEUTICS ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH STANFORD UNIVERSITY SCHOOL OF MEDICINE

Omega Therapeutics, Inc | October 14, 2021

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us